{
    "nctId": "NCT00327288",
    "briefTitle": "Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients",
    "officialTitle": "A Phase 1 Trial of Amplimexon\u00ae (Imexon, Inj.) Plus Taxotere\u00ae (Docetaxel) in Previously Treated Inoperable Stage III and Stage IV Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic Previously Treated Breast Cancer or Hormone Refractory Prostate Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Non-small Cell Lung Cancer, Breast Cancer, Prostate Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 34,
    "primaryOutcomeMeasure": "Determine the tolerability",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Be diagnosed with previously treated breast, lung, or prostate cancer where docetaxel is indicated.\n* Prior treatment; at least one prior regimen required.\n* Able to perform the activities of daily living.\n* Off prior cancer therapy for at least 4 weeks.\n* If female neither pregnant nor nursing.\n* Willing to use contraceptives to prevent pregnancy.\n* No other serious illnesses.\n* No other active malignancy.\n* No serious infections.\n* No other current drug therapy for the cancer.\n* Blood counts and blood chemistries in or near normal range.\n* Prior radiation is permitted.\n\nExclusion Criteria:\n\n* Active brain metastases.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}